CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Shanghai Fosun Pharmaceutical (Group) Company Limited Company Snapshot
Shanghai Fosun Pharmaceutical (Group) Company Limited operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Shanghai Fosun Pharmaceutical (Group) Company Limited with three other companies in this sector in China: Shenzhen Neptunus Bioengineer (2016 sales of 13.61 billion Chinese Renmimbi [US$1.97 billion] of which 84% was Pharmaceutical Distribution), Harbin Pharmaceutical Group Company Limited (14.13 billion Chinese Renmimbi [US$2.05 billion] of which 64% was Medicine Trade), and Tasly Pharmaceutical Group Company Limited (13.95 billion Chinese Renmimbi [US$2.02 billion] of which 51% was Medicine Commerce).

Sales Analysis. During the year ended December of 2016, sales at Shanghai Fosun Pharmaceutical (Group) Company Limited were 14.51 billion Chinese Renmimbi (US$2.11 billion). This is an increase of 16.0% versus 2015, when the company's sales were 12.50 billion Chinese Renmimbi. This was the fifth consecutive year of sales increases at Shanghai Fosun Pharmaceutical (Group) Company Limited (and since 2011, sales have increased a total of 124%). Sales of Healthcare saw an increase of 21.7% in 2016, from 1.38 billion Chinese Renmimbi to 1.68 billion Chinese Renmimbi. Not all segments of Shanghai Fosun Pharmaceutical (Group) Company Limited experienced an increase in sales in 2016: sales of Other Business Operations fell 29.5% to 26.62 million Chinese Renmimbi. (However, this segment's sales were only a very small portion of the company's overall sales).
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Shanghai Fosun Pharmaceutical (Group) Company Limited
  Stock Performance Chart for Shanghai Fosun Pharmaceutical (Group) Company Limited
 
  Stock Data: Recent Stock Performance:
  Current Price (5/26/2017): 31.03
(Figures in Chinese Renmimbi)
1 Week 1.2%   13 Weeks 5.0%  
4 Weeks 18.7%   52 Weeks 66.1%  
 
Shanghai Fosun Pharmaceutical (Group) Company Limited Key Data:
  Ticker: 600196 Country: China
  Exchanges: SHG Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2016 Sales 14,505,584,000
(Year Ending Jan 2017).
Employees: 19,523
  Currency: Chinese Renmimbi Market Cap: 74,922,307,360
  Fiscal Yr Ends: December Shares Outstanding: 2,414,512,000
  Share Type: A Gu Closely Held Shares: 1,074,557,768
 
 
Sponsored Links
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.